Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production

Adoptive cell transfer（ACT） using chimeric antigen receptor（CAR） modified T cells and T cell receptor（TCR） engineered T cells has shown therapeutic efficacy in cancer treatment 1,2 . CAR T cells are widely applicable to tumor patients because of their ability to directly identify tumor cells in an MHCindependent manner. Recent studies have shown that antigen escape, including antigenic heterogeneity,